Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity

Endocrinology

Volumn 154, Issue 6, 2013, Pages 1990-1998

  Zhang, XianTian ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; PROTEIN KINASE B; SHORT HAIRPIN RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CONTROLLED STUDY; DOWN REGULATION; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; HORMONE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TAMOXIFEN;

EID: 84878431592     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1116     Document Type: Article

References (29)

1. Macgregor JI, Jordan VG. Basic guide to the mechanisms of antiestrogens action. Phamacol Rev. 1998;50:151-196. (Pubitemid 28305723)
2. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogens action and resistance. Phamacol Rev. 2001;53:25-71. (Pubitemid 32173107)
3. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316-7339. (Pubitemid 37492898)
4. Normanno N, Di Maio M, De Maio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005;12:721-747. (Pubitemid 41815773)
5. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48:5183-5187.
6. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987;23:1189-1196. (Pubitemid 17112483)
7. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med. 2011;62:233-247.
8. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res. 2004;10:337S-345S. (Pubitemid 38116640)
9. Santen RJ. Clinical use of aromatase inhibitors in breast carcinoma. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine. 3rd ed. Philadelphia, PA: Lea & Febiger; 1993:865-877.
10. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev. 1990;11:221-265. (Pubitemid 20182870)
11. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80:2918-2925.
12. Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat. 2005;94:213-223. (Pubitemid 41677626)
13. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun. 2005;336:1023-1027. (Pubitemid 41383424)
14. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA. 2006;103:9063-9068. (Pubitemid 43902533)
15. Zou Y, Ding L, Coleman M, Wang ZY. Estrogen receptor-α (ER-α) suppresses expression of its variant ER-α36. FESEB Lett. 2009;583:1368-1374.
16. Shi L, Dong B, Li Z, et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009;27:3423-3429.
17. Lin SL, Yan LY, Zhang XT, et al. ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One. 2010;5:e9013.
18. Zhang XT, Ding L, Kang LG, Wang ZY. Estrogen receptor-α 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One. 2012;7:e30174.
19. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang Z. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30:770-780.
20. Abukhdeir AM, Vitolo MI, Argani P, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA. 2008;105(1):288-293.
21. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128:281-294. (Pubitemid 46123510)
22. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol . 2001;3:245-252.
23. Viglietto G, Motti ML, Fusco A. Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle. 2002;1:394-400.
24. Connor CE, Norris JD, Broadwater G, et al. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 2001;61:2917-2922. (Pubitemid 32691935)
25. Kang L, Guo Y, Zhang X, Meng J, Wang ZY. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol. 2011;127:262-268.
26. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028-2036. (Pubitemid 30305102)
27. Jordan VC, Lewis-Wambi J, Kim H, et al. Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen recepotr positive breast cancer patients. Breast. 2007;16(suppl 2):S105-S113.
28. Maximov PY, Lewis-Wambi JS, Jordan VC. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther. 2009;4:88-102.
29. Xie H, Sun M, Liao XB, et al. Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women. J Bone Miner Res. 2011;26:156-168.